Nelfinavir mesylate is under clinical development by Pfizer and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase II drugs for Multiple Myeloma (Kahler Disease) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nelfinavir mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nelfinavir mesylate overview
Nelfinavir Mesylate (Viracept) belongs to the class of protease inhibitors, acts as an antiretroviral drug . It is formulated as tablets, film coated tablets and powder for oral route of administration. It is indicated in antiretroviral combination treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children of 3 years of age and older. The drug candidate is under development for the treatment of multiple myeloma.
See Also:
Nelfinavir Mesylate is under development for the treatment of relpased or refractory multiple myeloma in the U.S. It was also under development for acute myelocytic leukemia, acute lymphocytic leukemia, diffuse large b-cell lymphoma, hodgkin lymphoma, mantle cell lymphoma, natural killer cell lymphomas, follicular lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphomas, cutaneous T-cell lymphoma, lymphoproliferative disorders, sezary syndrome, mycosis fungoides, T-cell leukemia, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, aggressive NK-cell leukemia, extranodal NK/T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, primary cutaneous T-cell lymphoma and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Nelfinavir mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
